Astaxanthin Softgels, graded Moderate-evidence on Magellan — commercial supplements typically supply about 4–12 mg per day of the naturally esterified pigment. The evidence is mixed and limited: meta-analyses of cardiometabolic outcomes find largely neutral-to-modest effects, wrinkle-depth reduction was not significant in meta-analysis, and pooled trials total only hundreds of participants, often from a small set of research groups.
Source: Front Endocrinol 2023, PMID 37020589 ↗ · Nutraceuticals & Cellular Energizers · How Magellan grades evidence · Study write-up · evidence confidence: high
Astaxanthin is a reddish xanthophyll carotenoid produced mainly by the microalga Haematococcus pluvialis and obtained in the diet from salmon, trout, shrimp and krill that accumulate it. It is a lipid-soluble antioxidant that quenches singlet oxygen and scavenges free radicals within cell membranes and modulates redox-sensitive signalling pathways such as NF-κB and Nrf2, thereby influencing oxidative-stress and inflammatory mediators. Commercial supplements typically supply about 4–12 mg per day of the naturally esterified pigment.
In humans, randomized trials and meta-analyses most consistently show that astaxanthin lowers the lipid-peroxidation marker malondialdehyde (MDA) and raises total antioxidant capacity and superoxide-dismutase activity, with additional signals for modest improvements in skin moisture and elasticity, fatigue, and some cognitive and motor measures. The evidence is mixed and limited: meta-analyses of cardiometabolic outcomes find largely neutral-to-modest effects, wrinkle-depth reduction was not significant in meta-analysis, and pooled trials total only hundreds of participants, often from a small set of research groups. Astaxanthin appears well tolerated and biologically active as an antioxidant, but no large trial has tested clinical endpoints, so anti-aging claims beyond skin and oxidative-stress markers are extrapolations. This evidence describes the compound astaxanthin and its mechanisms, not this specific commercial softgel product.
Peer-reviewed studies on the active compound — citations link to PubMed.
“Increased serum levels of total antioxidant capacity and SOD were observed after astaxanthin”
“astaxanthin significantly decreased plasma malondialdehyde, increased superoxide dismutase and total antioxidant capacity”
“ASX significantly increased TAC; significant reduction in MDA, alleviating oxidative stress”
“These findings suggest that FP-MD is well tolerated and can be effectively used to address joint pain in patients diagnosed with mild osteoarthritis, the main symptom of this condition.”
“However, no significant differences in the pain intensity and CRP levels were found after controlling for confounding factors (P > 0.05).”
“Compared with placebo, astaxanthin significantly reduced blood malondialdehyde concentration (standardized mean difference [SMD]: -0.95; 95% CI, -1.67 to -0.23; P = .01).”
Research describes the active mechanism and is not a claim about this specific product.
Across large randomized trials and meta-analyses, marine omega-3s reliably reduce serum…
Across meta-analyses and randomized trials, creatine monohydrate combined with…
Multiple meta-analyses of randomized trials indicate that oral zinc, started soon after…
In humans, MK-7 supplementation consistently improves vitamin K-status biomarkers —…
Yes — its active compound is linked to 22 peer-reviewed studies, summarized and cited above.
You can buy it on Amazon via the link above; Magellan earns a small affiliate commission at no extra cost to you, which does not affect the evidence grade.
Dietary supplements and devices are generally well tolerated but are not a substitute for medical care. Talk to your physician before starting, especially if you take medication or have a health condition.